메뉴 건너뛰기




Volumn 56, Issue 10, 2017, Pages 1771-1779

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: Clinical, structural and safety results

(15)  Smolen, Josef S a   Choe, Jung Yoon b   Prodanovic, Nenad c   Niebrzydowski, Jaroslaw d   Staykov, Ivan e   Dokoupilova, Eva f   Baranauskaite, Asta g   Yatsyshyn, Roman h   Mekic, Mevludin i   Porawska, Wieskawa j   Ciferska, Hana k   Jedrychowicz Rosiak, Krystyna d   Zielinska, Agnieszka l   Choi, Jasmine m   Rho, Young Hee m  


Author keywords

Biosimilar; Flixabi; Infliximab; Monoclonal antibody; Radiographic progression; Remicade; Renflexis; Rheumatoid arthritis; Sharp score; Tumour necrosis factor blocker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; DRUG ANTIBODY; FOLIC ACID; INFLIXIMAB; METHOTREXATE; SB 2; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

EID: 85029779740     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex254     Document Type: Article
Times cited : (50)

References (35)
  • 1
    • 84893772728 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    • Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
    • (2014) Ann Rheum Dis , vol.73 , pp. 492-509
    • Smolen, J.S.1    Landewe, R.2    Breedveld, F.C.3
  • 2
    • 79955826864 scopus 로고    scopus 로고
    • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    • Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
    • (2011) Ann Rheum Dis , vol.70 , pp. 896-904
    • Braun, J.1    van den Berg, R.2    Baraliakos, X.3
  • 3
    • 84960126976 scopus 로고    scopus 로고
    • European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
    • Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510
    • (2016) Ann Rheum Dis , vol.75 , pp. 499-510
    • Gossec, L.1    Smolen, J.S.2    Ramiro, S.3
  • 4
    • 0033524159 scopus 로고    scopus 로고
    • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
    • Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9
    • (1999) Lancet , vol.354 , pp. 1932-1939
    • Maini, R.1    St Clair, E.W.2    Breedveld, F.3
  • 5
    • 0033611472 scopus 로고    scopus 로고
    • A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    • Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
    • (1999) N Engl J Med , vol.340 , pp. 253-259
    • Weinblatt, M.E.1    Kremer, J.M.2    Bankhurst, A.D.3
  • 6
    • 84889688016 scopus 로고    scopus 로고
    • Inequities in access to biologic and synthetic DMARDs across 46 European countries
    • Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206
    • (2014) Ann Rheum Dis , vol.73 , pp. 198-206
    • Putrik, P.1    Ramiro, S.2    Kvien, T.K.3
  • 7
    • 84960851952 scopus 로고    scopus 로고
    • The changing landscape of biosimilars in rheumatology
    • Dö rner T, Strand V, Cornes P et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82
    • (2016) Ann Rheum Dis , vol.75 , pp. 974-982
    • Dörner, T.1    Strand, V.2    Cornes, P.3
  • 8
    • 84878622273 scopus 로고    scopus 로고
    • Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    • Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8
    • (2013) Autoimmun Rev , vol.12 , pp. 835-838
    • Modena, V.1    Bianchi, G.2    Roccatello, D.3
  • 9
    • 79959479569 scopus 로고    scopus 로고
    • Use of biologics in rheumatoid arthritis: current and emerging paradigms of care
    • Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011;33:679-707
    • (2011) Clin Ther , vol.33 , pp. 679-707
    • Curtis, J.R.1    Singh, J.A.2
  • 10
    • 33644952525 scopus 로고    scopus 로고
    • CHMP/437/04Rev1 (2 October 2016, date last accessed)
    • European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04Rev1. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2014/10/WC500176768.pdf (2 October 2016, date last accessed)
    • (2014) Guideline on similar biological medicinal products
  • 11
    • 85052631837 scopus 로고    scopus 로고
    • (2 October 2016, date last accessed)
    • US Food and Drug Administration. Biologics price competition and innovation. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ ucm216146.pdf. (2 October 2016, date last accessed)
    • Biologics price competition and innovation
  • 14
    • 85016808670 scopus 로고    scopus 로고
    • (27 February 2017, date last accessed). April
    • Remicade Prescribing Information. Janssen Biotech, Inc. April 2016. http://www.janssen.com/australia/sites/www_ janssen_com_australia/files/product/pdf/remicade_pi.pdf. (27 February 2017, date last accessed)
    • (2016) Janssen Biotech, Inc
  • 15
    • 84951020928 scopus 로고    scopus 로고
    • A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects
    • Shin D, Kim Y, Kim YS, Kö rnicke T, Fuhr R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects. Biodrugs 2015;29:381-8
    • (2015) Biodrugs , vol.29 , pp. 381-388
    • Shin, D.1    Kim, Y.2    Kim, Y.S.3    Körnicke, T.4    Fuhr, R.5
  • 16
    • 84941584714 scopus 로고    scopus 로고
    • A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
    • Choe J-Y, Prodanovic N, Niebrzydowski J et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015;76:58-64
    • (2015) Ann Rheum Dis , vol.76 , pp. 58-64
    • Choe, J.-Y.1    Prodanovic, N.2    Niebrzydowski, J.3
  • 17
    • 0034735842 scopus 로고    scopus 로고
    • Infliximab and methotrexate in the treatment of rheumatoid arthritis
    • Lipsky PE, van der Heijde D, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602
    • (2000) N Engl J Med , vol.343 , pp. 1594-1602
    • Lipsky, P.E.1    van der Heijde, D.2    St Clair, E.W.3
  • 18
    • 67449124635 scopus 로고    scopus 로고
    • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockage
    • Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockage. Ann Rheum Dis 2009;68:823-7
    • (2009) Ann Rheum Dis , vol.68 , pp. 823-827
    • Smolen, J.S.1    Han, C.2    van der Heijde, D.M.3
  • 19
    • 85052664041 scopus 로고    scopus 로고
    • (27 February 2017, date last accessed)
    • European Medicines Agency. Remicade: EPAR-product information (SmPC). 2016. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf (27 February 2017, date last accessed)
    • (2016) Remicade: EPAR-product information (SmPC)
  • 20
    • 0018882143 scopus 로고
    • Measurement of patient outcome in arthritis
    • Fries JF, Spitz P, Kraines RG et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
    • (1980) Arthritis Rheum , vol.23 , pp. 137-145
    • Fries, J.F.1    Spitz, P.2    Kraines, R.G.3
  • 21
    • 84859853303 scopus 로고    scopus 로고
    • Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice
    • Anderson J, Caplan L, Yazdany J et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7
    • (2012) Arthritis Care Res , vol.64 , pp. 640-647
    • Anderson, J.1    Caplan, L.2    Yazdany, J.3
  • 22
    • 79951506884 scopus 로고    scopus 로고
    • American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    • Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13
    • (2011) Ann Rheum Dis , vol.70 , pp. 404-413
    • Felson, D.T.1    Smolen, J.S.2    Wells, G.3
  • 23
    • 0032981611 scopus 로고    scopus 로고
    • How to read radiographs according to the Sharp/van der Heijde method
    • van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5
    • (1999) J Rheumatol , vol.26 , pp. 743-745
    • van der Heijde, D.1
  • 24
    • 84903597970 scopus 로고    scopus 로고
    • Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations
    • Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014;16:658-73
    • (2014) AAPS J , vol.16 , pp. 658-673
    • Shankar, G.1    Arkin, S.2    Cocea, L.3
  • 25
    • 84965033914 scopus 로고    scopus 로고
    • Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systemic review and meta-analysis of drug registries and health care databases
    • Souto A, Maneiro JR, Gó mez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systemic review and meta-analysis of drug registries and health care databases. Rheumatology 2016;55:523-34
    • (2016) Rheumatology , vol.55 , pp. 523-534
    • Souto, A.1    Maneiro, J.R.2    Gómez-Reino, J.J.3
  • 26
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial
    • Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81
    • (2004) Lancet , vol.363 , pp. 675-681
    • Klareskog, L.1    van der Heijde, D.2    de Jager, J.P.3
  • 27
    • 84938518501 scopus 로고    scopus 로고
    • Relationship between disease activity indices and their individual components and radiographic progression in RA: a systemic literature review
    • Navarro-Compá n V, Gherghe AM, Smolen JS et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systemic literature review. Rheumatology 2015;54:994-1007
    • (2015) Rheumatology , vol.54 , pp. 994-1007
    • Navarro-Compán, V.1    Gherghe, A.M.2    Smolen, J.S.3
  • 28
    • 17244364098 scopus 로고    scopus 로고
    • Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
    • Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
    • (2005) Arthritis Rheum , vol.52 , pp. 1020-1030
    • Smolen, J.S.1    Han, C.2    Bala, M.3
  • 29
    • 84874422827 scopus 로고    scopus 로고
    • Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis
    • Binder NB, Puchner A, Niederreiter B et al. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum 2013;65:608-17
    • (2013) Arthritis Rheum , vol.65 , pp. 608-617
    • Binder, N.B.1    Puchner, A.2    Niederreiter, B.3
  • 30
    • 34548183243 scopus 로고    scopus 로고
    • Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    • Rahman MU, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8
    • (2007) Ann Rheum Dis , vol.66 , pp. 1233-1238
    • Rahman, M.U.1    Strusberg, I.2    Geusens, P.3
  • 31
    • 84962037330 scopus 로고    scopus 로고
    • A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
    • Yoo DH, Racewicz A, Brzezicki J et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82
    • (2016) Arthritis Res Ther , vol.18 , pp. 82
    • Yoo, D.H.1    Racewicz, A.2    Brzezicki, J.3
  • 32
    • 84883746643 scopus 로고    scopus 로고
    • Biosimilars to treat inflammatory arthritis: the challenge of proving identity
    • Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93
    • (2013) Ann Rheum Dis , vol.72 , pp. 1589-1593
    • Kay, J.1    Smolen, J.S.2
  • 33
    • 84984596871 scopus 로고    scopus 로고
    • Clinical trials of biosimilars should become more similar
    • Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis 2017;76:4-6
    • (2017) Ann Rheum Dis , vol.76 , pp. 4-6
    • Kay, J.1    Isaacs, J.D.2
  • 34
    • 84980418189 scopus 로고    scopus 로고
    • United States Health Care Reform
    • Obama B. United States Health Care Reform. JAMA 2016;316:525-32
    • (2016) JAMA , vol.316 , pp. 525-532
    • Obama, B.1
  • 35
    • 84964570093 scopus 로고    scopus 로고
    • Editorial: biosimilars: new or dé jàvu?
    • Kay J. Editorial: biosimilars: new or dé jàvu? Arthritis Rheum 2016;68:1049-52
    • (2016) Arthritis Rheum , vol.68 , pp. 1049-1052
    • Kay, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.